GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene. As part of the PBS listing, the Government ...

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Nuformix plc (LON:NFX – Get Free Report)’s share price was down 10% on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 1,986,748 shares were ...

INR:6816. bubble slots AstraZeneca and Merck jointly announced that the PARP inhibitor Olaparib is expected to be approved by the end of the year Chinese data releas ...

INR:2657. new madhavrao scindia cricket stadium Olaparib Phase 3 clinical results show positive and significant prolongation of overall surv ...

INR:1670. rummy lee PARP inhibitor olaparib receives priority review for prostate cancer indication Lung cancer patients miss the 4+7 coverage expansion and spend an ex ...